Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

ACIP logoThe Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develop recommendations on use of vaccines in the civilian population of the United States...



Register for upcoming February ACIP meeting

February 22-23, 2017

Deadline for registration:
Non-US Citizens: February 1, 2017
US Citizens: February 13, 2017

Registration is NOT required to watch the live meeting webcast or to listen via telephone.

Public Comment Instructions [1 page]

ACIP Recommendations

General Committee-related Information

  • Charter
    Defines ACIP's purpose, authority, and function; its structure, meetings, and compensation; plus costs, reports, and termination.
  • Members
    Membership roster, including chair, executive secretary, voting members, ex officio members, and liaison representatives.
  • Articles
    Journal articles about the ACIP.


ACIP Flyer

ACIP brochure This ACIP flyer [2 pages] answers questions such as what does the ACIP consider in the vaccine recommendation process, including recommended ages for administration of various vaccines to children?

ACIP Votes, October 2016

  • ACIP approved the following four recommendations by majority vote on October 19, 2016:
    • Hepatitis B vaccine: birth dose within 24 hours of birth for medically stable infants weighing ≥2000 grams and born to HBsAg-negative mothers; removal of permissive language to delay the hepatitis B birth dose; approve revised statement.
    • Human papillomavirus vaccine: 2-dose schedule for boys and girls initiating HPV vaccination series at 9 to 14 years (0,6-12 months); 3-dose schedule for persons initiating HPV vaccination series at older ages; 3-dose schedule for immunocompromised persons.
    • Meningococcal vaccines: provided guidance on the updated dosing schedules for one serogroup B meningococcal vaccine, MenB-FHbp (Trumenba). For persons at increased risk for meningococcal disease and during serogroup B outbreaks, 3 doses of MenB-FHbp administered at 0, 1-2, and 6 months; when given to healthy adolescents not at increased risk for meningococcal disease, 2 doses of MenB-FHbp at 0 and 6 months.
    • Pertussis-containing vaccines: approve the updated statement, “Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the ACIP.”
  • The 2017 Child/Adolescent and Adult Immunization schedules were approved by majority vote on October 20, 2016.
  • If approved by the CDC Director, the recommendations will become official once published in MMWR.

ACIP Meetings